Aarti Drugs surged 7.05% to Rs 1,003.85, extending gains for the sixth session.
Shares of Aarti Drugs spurted 36.59% in six trading sessions from a recent closing low of Rs 734.89 hit on 29 September 2020.
The scrip hit an all-time high of Rs 1,025 today. It has soared 850.97% from its 52-week low of Rs 105.56 hit on 19 March 2020.
The company recently issued three bonus shares for each share held (3:1).
The drug maker's consolidated net profit surged 280.60% to Rs 85.45 crore on a 34.3% jump in net sales to Rs 544.67 crore in Q1 June 2020 over Q1 June 2019.
Aarti Drugs is a pharmaceutical company. The company has a strong presence in the anti-diarrhea, anti-inflammatory therapeutic groups. With its manufacturing facilities at Tarapur and Sarigam, the company manufactures vitamins, anti-arthritis, anti-fungal, antibiotics, ACE inhibitors, besides its range in anti-diabetic, anti-cholinergic, sedatives and anti-depressant drugs.
Powered by Capital Market - Live News
(This story has not been edited by Business Standard staff and is auto-generated from a syndicated feed.)
Business Standard has always strived hard to provide up-to-date information and commentary on developments that are of interest to you and have wider political and economic implications for the country and the world. Your encouragement and constant feedback on how to improve our offering have only made our resolve and commitment to these ideals stronger. Even during these difficult times arising out of Covid-19, we continue to remain committed to keeping you informed and updated with credible news, authoritative views and incisive commentary on topical issues of relevance.
We, however, have a request.
As we battle the economic impact of the pandemic, we need your support even more, so that we can continue to offer you more quality content. Our subscription model has seen an encouraging response from many of you, who have subscribed to our online content. More subscription to our online content can only help us achieve the goals of offering you even better and more relevant content. We believe in free, fair and credible journalism. Your support through more subscriptions can help us practise the journalism to which we are committed.
Support quality journalism and subscribe to Business Standard.